Cureva engineers clinical-grade peptide protocols, exosome therapeutics, and advanced molecular formulations for physicians and bio-optimizers.
Our peptide formulations utilize solid-phase peptide synthesis (SPPS) ensuring exact amino acid sequencing. From tissue repair vectors like BPC-157 to somatotropic signaling molecules, every batch is verified for exact molecular weight.
Beyond single molecules, Cureva isolates pure mesenchymal stem cell (MSC) derived exosomes. These nano-vesicles deliver potent growth factors and mRNA directly to damaged cells, overriding cellular senescence.
Verified by HPLC and Mass Spec. No filler amino acids.
Including secretagogues, neuro-peptides, and bioregulators.
Temperature-controlled priority logistics for clinics globally.
Select formulations currently available for research and clinical prescription.
Cureva operates strictly B2B and B2C through verified medical providers. To order direct formulations, an active medical license (MD, DO, NP, PA, ND) and a signed clinical partnership agreement must be on file.
Yes. Certificates of Analysis (COAs) provided by independent third-party laboratories (Janoshik, MZ Biolabs) are available for every batch. These verify structural integrity, mass, and absence of heavy metals/endotoxins.
All peptides are shipped in lyophilized (freeze-dried) powder format to ensure structural stability. Depending on the specific molecule, fragile blends are shipped using thermal packaging and expedited overnight logistics.
We supply bacteriostatic water (BAC) and sterile mixing apparatus exclusively to our clinical partners. Reconstitution protocols and volumetric dosing charts are accessible via the provider portal.